Today BICO, the world's leading Bio Convergence company announced it has added
"I've come across hundreds of life science companies during my career, but BICO's approach to converging biology and technology is unlike anything I've seen," said
Illumina is world leading in DNA sequencers and advancements in genomics are poised to drive significant healthcare breakthroughs in the coming decades. Illumina's efforts have already significantly bolstered the global response to the COVID-19 pandemic. A field that is also vitally important to BICO's business, with nearly all its subsidiaries selling into the industry. As the leader of Illumina's commercial organization, Tousi will bring invaluable strategic insights and recommendations that enable BICO to become a leading player in the field.
"We are very happy to welcome
Tousi has been with Illumina since 2012, and previously led the product development organization as Chief Product Officer. During that time, she was responsible for global engineering, consumables, sequencing applications, IVD, software and informatics development efforts as well as overseeing numerous key product launches and leading the acquisition of Edico Genomics, BlueBee, and Enancio.
For more information about Tousi's appointment and the Board of Directors, please visit: https://bico.com/investors
For further information, please contact:
Phone (
Email: il@bico.com
Phone (US):
Riley Munks, PR Manager: (650) 863-6699
Alyssa D'Orazio, PR Manager: (617) 634-9601
Email: press@bico.com
This information was submitted for publication, through the agency of the contact persons set out above, on
About BICO
Founded in 2016, BICO (formerly
With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group's instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com
https://news.cision.com/bico-group/r/bico-announces-appointment-of-susan-tousi-as-new-member-of-the-board-of-directors,c3455843
https://mb.cision.com/Main/14960/3455843/1497866.pdf
(c) 2021 Cision. All rights reserved., source